# EDGAR Filing Document

**Accession Number:** 0002007191
**File Stem:** 0002007191-26-000027
**Filing Date:** 2026-5
**Character Count:** 5498
**Document Hash:** f54b125f77db1707a54a827fa44ba12f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002007191-26-000027.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0002007191-26-000027

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 65

**CONFORMED PERIOD OF REPORT**: 20250520

**FILED AS OF DATE**: 20260521

**DATE AS OF CHANGE**: 20260521

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Telix Pharmaceuticals Ltd
- **CENTRAL INDEX KEY:** 0002007191
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42128
- **FILM NUMBER:** 261008520

**BUSINESS ADDRESS:**
- **STREET 1:** 55 FLEMINGTON ROAD
- **CITY:** NORTH MELBOURNE
- **STATE:** C3
- **ZIP:** 3051
- **BUSINESS PHONE:** 61 3 9093 3855

**MAIL ADDRESS:**
- **STREET 1:** 55 FLEMINGTON ROAD
- **CITY:** NORTH MELBOURNE
- **STATE:** C3
- **ZIP:** 3051

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May, 2026

Commission File Number: **001-42128**

**Telix Pharmaceuticals Limited**

(Translation of registrant's name into English)

**55 Flemington Road**

**North Melbourne, Victoria 3051, Australia**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

On May 21, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed three announcements with the Australian Securities Exchange, titled (i) "Telix Annual General Meeting Chairman and CEO Addresses," (ii) "Telix Annual General Meeting Presentation," and (iii) "Results of Annual General Meeting," copies of which are attached to this Form 6-K as Exhibits 99.1, 99.2, and 99.3, respectively.

---

| | |
|:---|:---|
| <u>[99.1](agmaddress26.htm)</u>  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ASX Announcement – AGM Addresses  |
| <u>[99.2](agmprez26.htm)</u>  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ASX Announcement – AGM Presentation  |
| [99.3](agmresults26.htm) | ASX Announcement – AGM Results |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Telix Pharmaceuticals Limited** | **Telix Pharmaceuticals Limited** |
| Date: May 21, 2026  | By:  | /s/ Christian Krautkramer |
|  |  | Name: Christian Krautkramer |
|  |  | Title: Group General Counsel |

---

------

## Exhibit 99.1

![agmaddress26.pdf page 1](image01.jpg)

![agmaddress26.pdf page 2](image02.jpg)

![agmaddress26.pdf page 3](image03.jpg)

![agmaddress26.pdf page 4](image04.jpg)

![agmaddress26.pdf page 5](image05.jpg)

![agmaddress26.pdf page 6](image06.jpg)

![agmaddress26.pdf page 7](image07.jpg)

![agmaddress26.pdf page 8](image08.jpg)

![agmaddress26.pdf page 9](image09.jpg)

![agmaddress26.pdf page 10](image10.jpg)

## Exhibit 99.2

![agmprez26.pdf page 1](agmprez261_1.jpg)

![agmprez26.pdf page 2](agmprez262_1.jpg)

![agmprez26.pdf page 3](agmprez263_1.jpg)

![agmprez26.pdf page 4](agmprez264_1.jpg)

![agmprez26.pdf page 5](agmprez265_1.jpg)

![agmprez26.pdf page 6](agmprez266_1.jpg)

![agmprez26.pdf page 7](agmprez267_1.jpg)

![agmprez26.pdf page 8](agmprez268_1.jpg)

![agmprez26.pdf page 9](agmprez269_1.jpg)

![agmprez26.pdf page 10](agmprez2610_1.jpg)

![agmprez26.pdf page 11](image11.jpg)

![agmprez26.pdf page 12](image12.jpg)

![agmprez26.pdf page 13](image13.jpg)

![agmprez26.pdf page 14](image14.jpg)

![agmprez26.pdf page 15](image15.jpg)

![agmprez26.pdf page 16](image16.jpg)

![agmprez26.pdf page 17](image17.jpg)

![agmprez26.pdf page 18](image18.jpg)

![agmprez26.pdf page 19](image19.jpg)

![agmprez26.pdf page 20](image20.jpg)

![agmprez26.pdf page 21](image21.jpg)

![agmprez26.pdf page 22](image22.jpg)

![agmprez26.pdf page 23](image23.jpg)

![agmprez26.pdf page 24](image24.jpg)

![agmprez26.pdf page 25](image25.jpg)

![agmprez26.pdf page 26](image26.jpg)

![agmprez26.pdf page 27](image27.jpg)

![agmprez26.pdf page 28](image28.jpg)

![agmprez26.pdf page 29](image29.jpg)

![agmprez26.pdf page 30](image30.jpg)

![agmprez26.pdf page 31](image31.jpg)

![agmprez26.pdf page 32](image32.jpg)

![agmprez26.pdf page 33](image33.jpg)

![agmprez26.pdf page 34](image34.jpg)

![agmprez26.pdf page 35](image35.jpg)

![agmprez26.pdf page 36](image36.jpg)

![agmprez26.pdf page 37](image37.jpg)

![agmprez26.pdf page 38](image38.jpg)

![agmprez26.pdf page 39](image39.jpg)

![agmprez26.pdf page 40](image40.jpg)

![agmprez26.pdf page 41](image41.jpg)

![agmprez26.pdf page 42](image42.jpg)

![agmprez26.pdf page 43](image43.jpg)

![agmprez26.pdf page 44](image44.jpg)

![agmprez26.pdf page 45](image45.jpg)

![agmprez26.pdf page 46](image46.jpg)

## Exhibit 99.3

![agmresults26.pdf page 1](agmresults261_1.jpg)

![agmresults26.pdf page 2](agmresults262_1.jpg)

![agmresults26.pdf page 3](agmresults263_1.jpg)

![agmresults26.pdf page 4](agmresults264_1.jpg)

![agmresults26.pdf page 5](agmresults265_1.jpg)